目的：阐明曲妥珠单抗的反应与 TIM-3 和 FOXP-3 免疫检查点分子表达之间的关系。 材料与方法：采用 qPCR 分析外周血中 FOXP-3 和 TIM-3 的表达，以及曲妥珠单抗的血清水平使用免疫吸附酶测定法估计。结果：在曲妥珠单抗治疗期间，FOXP-3 基因表达在一年的治疗期间显示出显着下降，从第 9 个周期的 0.85 降至第 17 个周期的 0.75。表达量在第 9 个循环时显着上调至 2.8 倍，随后参考基因表达字体的倍数变化从 2.8 减少至 1.7。 结论：FOXP-3 和 TIM-3 有可能成为提示性标记物可以预测曲妥珠单抗的反应，但无法预测复发的可能性。

Aim: To clarify the association between response to Trastuzumab and molecular expression of TIM-3 and FOXP-3 immune checkpoints.Materials and Methods: FOXP-3 and TIM-3 expression in peripheral blood was analyzed using qPCR, and the serum level of Trastuzumab was estimated using an immune sorbent enzyme assay.Results: During treatment with Trastuzumab, the FOXP-3 gene expression showed a significant decline throughout one year of treatment, going from 0.85 at cycle 9 to 0.75 at cycle 17. While the TIM-3 gene expression showed a significant up regulation at cycle 9 to 2.8 fold, followed by a reduction in the fold change from 2.8 to 1.7 in the font of reference gene expression.Conclusions:FOXP-3 and TIM-3 have the potential to be suggestive markers that can anticipate the response to Trastuzumab, but they are not capable of predicting the likelihood of recurrence.